BALCHEM CORPORATION— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$264M
↑+9.8% +$24Mvs FY2024 (Q4)
Gross Profit
$94M
↑+8.8% +$8Mvs FY2024 (Q4)
Operating Income
$52M
↑+10.2% +$5Mvs FY2024 (Q4)
Net Income
$39M
↑+16.8% +$6Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $264M | $240M |
| COGS | $170M | $154M |
| Gross Profit | $94M | $86M |
| R&D | $5M | $5M |
| SG&A | $0 | $0 |
| D&A | $12M | $11M |
| Other OpEx | $25M | $23M |
| Operating Income | $52M | $47M |
| Interest Exp. | $2M | $3M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $50M | $44M |
| Tax | $11M | $11M |
| Net Income | $39M | $34M |
QuarterCharts · SEC EDGAR data · BCPC · Comparing FY2025 (Q4) vs FY2024 (Q4)